Log In
Print
BCIQ
Print
Print this Print this
 

IV Erwinaze

  Manage Alerts
Collapse Summary General Information
Company Jazz Pharmaceuticals plc
DescriptionIV formulation of Erwinia chrysanthemi-derived asparaginase
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase I
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to Escherichia coli-derived asparaginase
Regulatory Designation

Partner

Ohara Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today